Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03983954
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:54.931221+00:00
Published At
2025-11-28T00:00:00+00:00
Record Updated At
2025-11-28
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["ER+ Breast Cancer", "Ovarian Cancer", "Cervical Squamous Cell Carcinoma", "Pancreatic Adenocarcinoma", "Endometrial Cancer", "Renal Cell Carcinoma", "Urothelial Cancer", "Head and Neck Squamous Cell Carcinoma", "Mesothelioma", "Melanoma", "Hepatocellular Carcinoma", "Prostate Cancer", "NSCLC", "HER2-negative Breast Cancer", "Triple Negative Breast Cancer", "Bladder Cancer", "Colorectal Cancer Metastatic", "GastroEsophageal Cancer", "NSCL2 Gene Mutation", "Esophageal Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-11-28"
protocolSection.identificationModule.nctId
"NCT03983954"
protocolSection.identificationModule.officialTitle
"Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid Tumors"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • ER+ Breast Cancer (protocolSection.conditionsModule.conditions)
  • Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Cervical Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Cancer (protocolSection.conditionsModule.conditions)
  • Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Urothelial Cancer (protocolSection.conditionsModule.conditions)
  • Head and Neck Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Mesothelioma (protocolSection.conditionsModule.conditions)
  • Melanoma (protocolSection.conditionsModule.conditions)
  • Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Prostate Cancer (protocolSection.conditionsModule.conditions)
  • NSCLC (protocolSection.conditionsModule.conditions)
  • HER2-negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Triple Negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Bladder Cancer (protocolSection.conditionsModule.conditions)
  • Colorectal Cancer Metastatic (protocolSection.conditionsModule.conditions)
  • GastroEsophageal Cancer (protocolSection.conditionsModule.conditions)
  • NSCL2 Gene Mutation (protocolSection.conditionsModule.conditions)
  • Esophageal Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.